Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trialMohamed Hussein, Asim Alsaedi, Yasser Mandourah et al.|Trials|2018Cited by 261
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trialMohamed Hussein, Yaseen M. Arabi, Ayed Y. Asiri et al.|Trials|2020Cited by 132
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory SyndromeYaseen M. Arabi, Adel Alothman, Ayed Y. Asiri et al.|New England Journal of Medicine|2020Cited by 80
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trialFaizah Alotaibi, Naif Khalaf Alharbi, Lindsey B. Rosen et al.|Influenza and Other Respiratory Viruses|2023Cited by 52
The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)Mohammed Al Ghobain, Majed Al Jeraisy, Fatimah Rebh et al.|Journal of Infection and Public Health|2022Cited by 6